ContractInvizyne Technologies Inc • April 17th, 2024 • Biological products, (no disgnostic substances)
THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED IN THIS SAFE AND UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.
TERM EQUITY PURCHASE AGREEMENTTerm Equity Purchase Agreement • February 9th, 2024 • Invizyne Technologies Inc • Texas
This five-year term equity purchase agreement is entered into as of April 17, 2019 (this “Agreement”), by and between Invizyne Technologies, Inc., a Nevada corporation (the “Company”), and MDB Capital Group, LLC, a Texas limited liability company (the “Investor”).
Member FINRA/SIPCInvizyne Technologies Inc • April 17th, 2024 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) will confirm the basis upon which Invizyne Technologies Inc. (the “Company”) has engaged Digital Offering, LLC (together with its affiliates, control persons, officers, directors, employees and agents, “Digital Offering”), to act as Company’s qualified independent underwriter in in connection with an offering of the common stock of Invizyne Technologies Inc. (the “Company”) and such other securities as may be necessary for a successful offering (collectively referred herein as the “Securities”), on terms and conditions to be mutually agreed between the Company and the Qualified Independent Underwriter (the “Offering”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • February 9th, 2024 • Invizyne Technologies Inc • Nevada
This Indemnification Agreement (“Agreement”) is made as of the ___th day of April 20___ and between Invizyne Technologies Inc., a Nevada corporation (“Company”), and ___ (the “Indemnitee”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 17th, 2024 • Invizyne Technologies Inc • Biological products, (no disgnostic substances) • California
This exclusive license agreement (“Agreement”) is made effective this 25th day of April, 2019 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (“The Regents”), acting through The Technology Development Group of the University of California, Los Angeles (“UCLA”), located at 10889 Wilshire Boulevard, Suite 920, Los Angeles, CA 90095-7191, and lnvizyne Technologies, Inc. (“Licensee”), a Nevada corporation having a principal place of business at 40 Hitching Post Drive, Rolling Hills Estates, CA 90274.
ContractInvizyne Technologies Inc • February 9th, 2024
THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED IN THIS SAFE AND UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.
EXECUTIVE employment AGREEMENTExecutive Employment Agreement • April 17th, 2024 • Invizyne Technologies Inc • Biological products, (no disgnostic substances) • California
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 12, 2024, by and between Michael Heltzen (“Executive”) and Invizyne Technologies, Inc., a Nevada corporation (the “Company” and together with Executive, the “Parties”).
